NFX Stock Overview
Operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nuformix plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.0044 |
| 52 Week Low | UK£0.0004 |
| Beta | 0.99 |
| 1 Month Change | 6.38% |
| 3 Month Change | -21.01% |
| 1 Year Change | -82.14% |
| 3 Year Change | -95.56% |
| 5 Year Change | -99.40% |
| Change since IPO | -98.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| NFX | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -4.8% | -1.7% | -2.6% |
| 1Y | -82.1% | -3.5% | 2.4% |
Return vs Industry: NFX underperformed the UK Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: NFX underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| NFX volatility | |
|---|---|
| NFX Average Weekly Movement | 12.7% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: NFX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: NFX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3 | n/a | www.nuformix.com |
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Nuformix plc Fundamentals Summary
| NFX fundamental statistics | |
|---|---|
| Market cap | UK£409.65k |
| Earnings (TTM) | -UK£477.88k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs NFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NFX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£477.89k |
| Earnings | -UK£477.88k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NFX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:28 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuformix plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Davison | Allenby Capital Limited |